This is a non-core endpoint: only basic statistics are computed.
See its core counterpart C3_VAGINA_EXALLC for full statistics.
Malignant neoplasm of vagina
C3_VAGINA
Vaginal neoplasm: Tumors or cancer of the VAGINA.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleonly females |
293373 |
2. Check conditionsNone |
293373 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
60 |
4. Check minimum number of eventsNone |
60 |
5. Include endpointsNone |
60 |
6. Filter based on genotype QC (FinnGen only) |
60 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF9
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of vagina
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of vagina, excluding all cancers (controls excluding all cancers)
- malignant neoplasm of female genital organs
- malignant neoplasm of female genital organs, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm
- Any event in cancer register
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 60 | 60 | - |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | - |
| Median age at first event (years) | 61.44 | 61.44 | - |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 50
- Matched controls
- 499
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
8070/3-C52.9
ICD-O-3
Squamous cell carcinoma, NOS, of vagina, NOS
+∞
35.8
30
*
C52.91
ICD-10 Finland
Squamous cell carcinoma of the vagina
+∞
34.4
29
*
LEB00
NOMESCO Finland
Biopsy of vagina
655.9
32.9
29
*
128
Kela drug reimbursment
Cancers of female genital organs
112.7
26.4
27
5
C52.90
ICD-10 Finland
Malignant neoplasm of vagina without histologic examination
+∞
15.4
14
*
JN2DG
NOMESCO Finland
Very extensive MRI examination of lower part of abdoment with high intensity magnet
+∞
14.2
13
*
WF002
NOMESCO Finland
Radical radiotherapy
69.6
13.7
15
*
C52
ICD-10 Finland
Malignant neoplasm of vagina
+∞
13.1
12
*
ULA02
NOMESCO Finland
Kolposcopy
13.2
12.3
23
30
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
85.6
12.3
13
*
C52.99
ICD-10 Finland
Malignant tumor of the vagina, unspecified histology
+∞
11.9
11
*
A03FA01
ATC
metoclopramide; systemic, rectal
9.1
11.8
32
81
JN2CG
NOMESCO Finland
Extensive MRI examination of lower part of abdoment with high intensity magnet
77.0
11.2
12
*
ZX040
NOMESCO Finland
Intracavity HDR radiotherapy
+∞
10.8
10
*
YJ2VG
NOMESCO Finland
MRI examination of pelvis with high intensity magnet for dose design of radiotherapy
+∞
10.8
10
*
JN4BD
NOMESCO Finland
Extensive body CT
12.6
10.3
19
23
WF003
NOMESCO Finland
Adjuvant radiotherapy
24.4
9.5
13
7
XLD00
NOMESCO Finland
Sytologyspecimen from mouth of uterus
9.0
9.5
22
40
LC2BE
NOMESCO Finland
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
6.9
9.4
34
117
LX1AE
NOMESCO Finland
Gynecological ultrasound examination as part of clinical examination
10.6
9.0
18
25
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
15.6
8.7
14
12
UKC02
NOMESCO Finland
Cystoscopy
8.1
8.6
21
41
LEC00
NOMESCO Finland
Partial excision of vagina
+∞
8.6
8
*
LFB00
NOMESCO Finland
Biopsy of vulva or perineum
17.0
8.4
13
10
LX1XE
NOMESCO Finland
Other gynecological ultrasound examination
14.1
7.8
13
12
H02AB02
ATC
dexamethasone; systemic
7.6
7.7
19
37
LEB10
NOMESCO Finland
Excision of lesion of vagina
93.4
7.6
8
*
C52.92
ICD-10 Finland
Adenocarcinoma of the vagina
+∞
7.5
7
*
ZX095
NOMESCO Finland
Combined chemoradiotherapy
+∞
7.5
7
*
XX3DW
NOMESCO Finland
Time consuming IT work
9.2
7.2
15
22
A04AA01
ATC
ondansetron; systemic, rectal
9.2
7.2
15
22
WW500
NOMESCO Finland
Blood transfusion
17.4
6.7
10
7
LAF10
NOMESCO Finland
Bilateral salpingo-oophorectomy
13.7
6.7
11
10
A04AD12
ATC
aprepitant; systemic
31.0
6.4
8
*
WC105
NOMESCO Finland
Simple cytostatic therapy of local tumor recidive
+∞
6.4
6
*
D39.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other female genital organs
+∞
6.4
6
*
YL1AD
NOMESCO Finland
CT examination of pelvis for dose design of radiotherapy
+∞
6.4
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
26
87
4.51
7.35
8.0
2.6
0.7
0.8
mmol/l
3.10
26
80
10
13
9.03
7.35
1.3
1.2
—
—
—
0
0
5
0
+∞
5.27
1.2
0.0
—
—
—
0
0
5
0
+∞
5.27
1.2
0.0
—
—
—
0
0
32
164
3.04
4.30
4.0
3.0
28.2
27.6
u/l
0.09
32
155
24
108
3.04
4.00
2.1
1.2
—
—
—
0
0
35
195
2.91
3.95
5.5
3.4
—
—
—
0
0
17
65
3.25
3.69
13.6
7.2
—
—
—
0
0
11
32
3.98
3.52
2.8
1.4
—
—
—
0
0
45
308
2.84
3.12
24.2
9.7
3.4
3.9
e9/l
1.07
45
271
15
62
2.89
2.81
11.5
4.1
103.3
103.8
mmol/l
0.12
15
57
6
10
6.52
2.77
1.8
4.4
3.3
3.5
g/l
—
6
10
15
64
2.79
2.64
4.3
2.9
12.4
6.5
umol/l
0.51
15
54
6
11
5.92
2.61
1.8
4.3
185.0
208.9
%
—
6
11
40
275
2.36
2.49
7.6
5.7
0.0
0.0
estimate
—
5
52
40
279
2.30
2.35
6.6
4.2
0.0
0.0
estimate
—
8
53
36
242
2.22
2.30
7.5
4.6
—
—
—
0
0
26
158
2.14
2.09
4.5
3.5
0.6
0.4
e6/l
0.43
26
116
13
58
2.58
2.08
2.4
5.8
221.9
277.5
u/l
1.13
13
52
6
17
3.80
1.89
1.0
1.1
—
—
—
0
0
20
116
2.09
1.77
5.4
2.5
—
—
—
0
0
37
274
1.91
1.59
6.8
4.2
0.0
0.0
estimate
—
8
55
23
146
1.93
1.57
8.9
4.6
0.0
0.0
estimate
—
7
58
5
15
3.53
1.55
1.4
2.4
—
—
—
0
0
30
211
1.84
1.48
2.9
3.9
119.5
42.4
ng/l
0.33
23
154
16
91
2.03
1.47
2.4
1.8
—
—
—
0
0
5
16
3.31
1.47
1.6
1.4
—
—
—
0
0
5
16
3.31
1.47
1.2
1.8
—
—
—
0
0
5
17
3.11
1.38
1.6
1.4
—
—
—
0
0
8
37
2.34
1.27
2.5
2.2
522.5
92.1
ng/l
—
8
32
12
66
2.02
1.19
2.6
1.8
—
—
—
0
0
12
67
1.99
1.14
2.4
1.7
—
—
—
0
0
6
28
2.27
0.94
1.5
1.4
—
—
—
0
0
6
29
2.18
0.92
2.8
1.3
—
—
—
0
0
5
23
2.28
0.78
4.0
8.2
23.9
25.2
mmol/l
—
5
23
5
25
2.09
0.74
7.4
3.1
47.1
43.5
%
—
5
25
10
62
1.74
0.70
12.8
4.1
1.1
1.0
mmol/l
—
10
53
27
215
1.47
0.69
8.1
4.3
—
—
—
0
0
35
295
1.45
0.65
10.9
6.1
1.2
1.2
mmol/l
1.57
30
246
8
50
1.69
0.64
7.3
3.4
139.1
75.5
ng/l
—
8
44
8
51
1.65
0.64
3.1
4.4
—
—
—
0
0
6
95
0.59
0.58
1.0
1.5
—
—
—
0
0
6
40
1.55
0.53
3.5
5.7
4.8
5.0
kpa
—
6
33
5
33
1.56
0.42
6.4
4.0
1.6
1.4
%
—
5
33
0
15
0.00
0.42
0.0
1.2
—
—
—
0
0
0
16
0.00
0.41
0.0
1.5
—
—
—
0
0
0
18
0.00
0.40
0.0
1.2
—
—
—
0
0
0
18
0.00
0.40
0.0
1.6
—
—
—
0
0
15
117
1.38
0.40
1.3
1.9
415.5
500.9
pmol/l
0.78
15
91
25
221
1.22
0.26
4.2
2.7
224.8
86.5
ug/l
1.12
20
195
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
54
550
0.82
0.20
18.5
11.0
23.0
22.6
u/l
0.09
54
523
53
543
0.80
0.19
35.4
16.7
138.7
139.8
mmol/l
2.05
53
523
53
542
0.81
0.19
35.2
16.9
4.0
3.9
mmol/l
0.54
53
522
47
485
0.86
0.11
22.6
14.3
71.6
76.6
ml/min/173m2
0.71
42
393
53
519
1.18
0.07
30.0
15.0
29.2
21.8
mg/l
1.09
48
397
13
142
0.89
0.07
2.3
3.0
438.4
6844.4
umol/l
1.04
13
116
29
301
0.93
0.05
2.8
2.6
—
—
—
0
0
13
121
1.09
0.04
1.2
1.2
0.5
1.5
u/ml
—
5
25
24
235
1.04
0.00
1.8
2.0
79.4
107.7
pmol/l
2.98
12
88
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
3.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
54
540
1.00
0.00
33.4
17.3
82.4
70.4
umol/l
0.59
54
540
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_VAGINA – Malignant neoplasm of vagina
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).